Buciuman Nikolett, Marcu Loredana G
Faculty of Physics, West University of Timisoara, Timisoara, Romania.
OncoHelp Foundation, Timisoara, Romania.
Eur Arch Otorhinolaryngol. 2022 Nov;279(11):5311-5321. doi: 10.1007/s00405-022-07452-1. Epub 2022 May 22.
A planning study was performed to evaluate dosimetric differences between intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) for head and neck cancer (HNC) for sequential boost (Seq-boost) and simultaneous integrated boost techniques (SIB).
30 patients with HNC were included, 15 treated with SIB and 15 with Seq-Boost. For all patients both VMAT and IMRT plans were completed. The planning objective for PTV was 95% of dose covering minimum 95% of PTV; for spinal cord and brainstem Dmax was limited to 45 Gy and 54 Gy respectively. The parotids had a mean dose < 26 Gy limitation. The number of monitor units (MU) were scored for treatment delivery time efficiency.
Both techniques achieved the set objectives regarding PTV coverage and organ sparing. SIB plans presented a statistically significant better homogeneity for VMAT (p = 0.0096), while Seq-boost showed a statistically significant better conformity for VMAT (p = 0.0049). For parotids only SIB plans showed a lower Dmean value obtained with VMAT, while Seq-boost plans showed statistically insignificant differences. For SIB plans the MU was reduced by 33.4% with VMAT, whereas in Seq-boost plans the reduction was by 19.1%.
VMAT shows dosimetric superiority to IMRT in some cases, however an adequate coverage of the target volumes and a suitable OAR sparing can be achieved with both techniques. Though IMRT is still the standard in HNC radiotherapy, VMAT can be safely implemented, offering at least similar target coverage and organ sparing, with significantly reduced MU.
进行一项规划研究,以评估调强放射治疗(IMRT)和容积调强弧形治疗(VMAT)在头颈部癌(HNC)序贯加量(Seq-boost)和同步整合加量技术(SIB)中的剂量学差异。
纳入30例HNC患者,15例接受SIB治疗,15例接受Seq-boost治疗。为所有患者完成VMAT和IMRT计划。计划靶体积(PTV)的规划目标是95%的剂量覆盖至少95%的PTV;脊髓和脑干的最大剂量(Dmax)分别限制在45 Gy和54 Gy。腮腺的平均剂量<26 Gy。记录监测单位(MU)数量以评估治疗实施时间效率。
两种技术均实现了关于PTV覆盖和器官保护的既定目标。SIB计划在VMAT中显示出统计学上显著更好的均匀性(p = 0.0096),而Seq-boost在VMAT中显示出统计学上显著更好的适形性(p = 0.0049)。仅对于腮腺,SIB计划显示VMAT获得的平均剂量(Dmean)值较低,而Seq-boost计划显示统计学上无显著差异。对于SIB计划,VMAT使MU减少了33.4%,而在Seq-boost计划中减少了19.1%。
VMAT在某些情况下显示出比IMRT更好的剂量学优势,然而两种技术均可实现靶区的充分覆盖和合适的危及器官保护。尽管IMRT仍是HNC放射治疗的标准,但VMAT可以安全实施,提供至少相似的靶区覆盖和器官保护,且MU显著减少。